These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 18628527)

  • 1. Selective loss of MEG3 expression and intergenic differentially methylated region hypermethylation in the MEG3/DLK1 locus in human clinically nonfunctioning pituitary adenomas.
    Gejman R; Batista DL; Zhong Y; Zhou Y; Zhang X; Swearingen B; Stratakis CA; Hedley-Whyte ET; Klibanski A
    J Clin Endocrinol Metab; 2008 Oct; 93(10):4119-25. PubMed ID: 18628527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Silencing of the imprinted DLK1-MEG3 locus in human clinically nonfunctioning pituitary adenomas.
    Cheunsuchon P; Zhou Y; Zhang X; Lee H; Chen W; Nakayama Y; Rice KA; Tessa Hedley-Whyte E; Swearingen B; Klibanski A
    Am J Pathol; 2011 Oct; 179(4):2120-30. PubMed ID: 21871428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional characterization of DLK1/MEG3 locus on chromosome 14q32.2 reveals the differentiation of pituitary neuroendocrine tumors.
    Chen Y; Gao H; Liu Q; Xie W; Li B; Cheng S; Guo J; Fang Q; Zhu H; Wang Z; Wang J; Li C; Zhang Y
    Aging (Albany NY); 2020 Dec; 13(1):1422-1439. PubMed ID: 33472171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression analysis of GADD45γ, MEG3, and p8 in pituitary adenomas.
    Binse I; Ueberberg B; Sandalcioglu IE; Flitsch J; Luedecke DK; Mann K; Petersenn S
    Horm Metab Res; 2014 Aug; 46(9):644-50. PubMed ID: 25126861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inactivation of the p16 gene in human pituitary nonfunctioning tumors by hypermethylation is more common in null cell adenomas.
    Ruebel KH; Jin L; Zhang S; Scheithauer BW; Lloyd RV
    Endocr Pathol; 2001; 12(3):281-9. PubMed ID: 11740049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Temple syndrome in a patient with variably methylated CpGs at the primary MEG3/DLK1:IG-DMR and severely hypomethylated CpGs at the secondary MEG3:TSS-DMR.
    Kagami M; Yanagisawa A; Ota M; Matsuoka K; Nakamura A; Matsubara K; Nakabayashi K; Takada S; Fukami M; Ogata T
    Clin Epigenetics; 2019 Mar; 11(1):42. PubMed ID: 30846001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of neuro D1 in human normal pituitaries and pituitary adenomas.
    Oyama K; Sanno N; Teramoto A; Osamura RY
    Mod Pathol; 2001 Sep; 14(9):892-9. PubMed ID: 11557786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased methylation upstream of the MEG3 promotor is observed in acute myeloid leukemia patients with better overall survival.
    Sellers ZP; Bolkun L; Kloczko J; Wojtaszewska ML; Lewandowski K; Moniuszko M; Ratajczak MZ; Schneider G
    Clin Epigenetics; 2019 Mar; 11(1):50. PubMed ID: 30876483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of cell growth negative regulators MEG3 and GADD45γ is lost in most sporadic human pituitary adenomas.
    Mezzomo LC; Gonzales PH; Pesce FG; Kretzmann Filho N; Ferreira NP; Oliveira MC; Kohek MB
    Pituitary; 2012 Sep; 15(3):420-7. PubMed ID: 21850407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypermethylation of delta-like homolog 1/maternally expressed gene 3 loci in human umbilical veins: insights into offspring vascular dysfunction born after preeclampsia.
    Yu YC; Jiang Y; Yang MM; He SN; Xi X; Xu YT; Hu WS; Luo Q
    J Hypertens; 2019 Mar; 37(3):581-589. PubMed ID: 30234781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of imprinting and allelic switching at the DLK1-MEG3 locus in human hepatocellular carcinoma.
    Anwar SL; Krech T; Hasemeier B; Schipper E; Schweitzer N; Vogel A; Kreipe H; Lehmann U
    PLoS One; 2012; 7(11):e49462. PubMed ID: 23145177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypermethylation of the promoter region is associated with the loss of MEG3 gene expression in human pituitary tumors.
    Zhao J; Dahle D; Zhou Y; Zhang X; Klibanski A
    J Clin Endocrinol Metab; 2005 Apr; 90(4):2179-86. PubMed ID: 15644399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of neuronatin expression is associated with promoter hypermethylation in pituitary adenoma.
    Revill K; Dudley KJ; Clayton RN; McNicol AM; Farrell WE
    Endocr Relat Cancer; 2009 Jun; 16(2):537-48. PubMed ID: 19218280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigenetic silencing of genes and microRNAs within the imprinted Dlk1-Dio3 region at human chromosome 14.32 in giant cell tumor of bone.
    Lehner B; Kunz P; Saehr H; Fellenberg J
    BMC Cancer; 2014 Jul; 14():495. PubMed ID: 25005035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of adrenocorticotropin receptor messenger ribonucleic acid in the human pituitary and its loss of expression in pituitary adenomas.
    Morris DG; Kola B; Borboli N; Kaltsas GA; Gueorguiev M; McNicol AM; Ferrier R; Jones TH; Baldeweg S; Powell M; Czirják S; Hanzély Z; Johansson JO; Korbonits M; Grossman AB
    J Clin Endocrinol Metab; 2003 Dec; 88(12):6080-7. PubMed ID: 14671214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. METTL3-mediated RNA m6A Hypermethylation Promotes Tumorigenesis and GH Secretion of Pituitary Somatotroph Adenomas.
    Chang M; Wang Z; Gao J; Yang C; Feng M; Niu Y; Tong WM; Bao X; Wang R
    J Clin Endocrinol Metab; 2022 Jan; 107(1):136-149. PubMed ID: 34491359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of the growth hormone secretagogue receptor in pituitary adenomas and other neuroendocrine tumors.
    Korbonits M; Jacobs RA; Aylwin SJ; Burrin JM; Dahia PL; Monson JP; Honegger J; Fahlbush R; Trainer PJ; Chew SL; Besser GM; Grossman AB
    J Clin Endocrinol Metab; 1998 Oct; 83(10):3624-30. PubMed ID: 9768675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meg3-DMR, not the Meg3 gene, regulates imprinting of the Dlk1-Dio3 locus.
    Zhu W; Botticelli EM; Kery RE; Mao Y; Wang X; Yang A; Wang X; Zhou J; Zhang X; Soberman RJ; Klibanski A; Zhou Y
    Dev Biol; 2019 Nov; 455(1):10-18. PubMed ID: 31301299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pituitary-derived MEG3 isoform functions as a growth suppressor in tumor cells.
    Zhang X; Zhou Y; Mehta KR; Danila DC; Scolavino S; Johnson SR; Klibanski A
    J Clin Endocrinol Metab; 2003 Nov; 88(11):5119-26. PubMed ID: 14602737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Somatostatin receptor subtypes mRNA in TSH-secreting pituitary adenomas: a case showing a dramatic reduction in tumor size during short octreotide treatment.
    Horiguchi K; Yamada M; Umezawa R; Satoh T; Hashimoto K; Tosaka M; Yamada S; Mori M
    Endocr J; 2007 Jun; 54(3):371-8. PubMed ID: 17420609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.